- Home
- KG vs ALDX Comparison
KG vs ALDX Comparison
Compare KG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KG | ALDX |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Bermuda | United States |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 103.1M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | KG | ALDX |
|---|---|---|
| Price | $11.27 | $1.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 4.7K | ★ 1.2M |
| Earning Date | 05-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.07 | $1.07 |
| 52 Week High | $31.45 | $6.18 |
Technical Indicators
Market Signals| Indicator | KG | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 53.64 |
| Support Level | $10.63 | $1.49 |
| Resistance Level | $12.30 | $1.91 |
| Average True Range (ATR) | 0.75 | 0.15 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 13.57 | 42.02 |
Price Performance
Historical ComparisonAbout KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.